
https://www.science.org/content/blog-post/bristol-myers-squibb-exits-diabetes
# Bristol-Myers Squibb Exits Diabetes (December 2013)

## 1. SUMMARY
The article reports that Bristol-Myers Squibb (BMS) announced its complete exit from the diabetes business in December 2013, selling its diabetes collaboration back to AstraZeneca (AZ). As part of the transaction, most BMS employees dedicated to diabetes would transfer to AstraZeneca, while some R&D and manufacturing staff would remain temporarily to transition the portfolio.

The author notes this move aligned with BMS's strategic shift toward its oncology portfolio, which the company viewed as offering better opportunities compared to diabetes—a sector perceived as slow-moving with insufficient returns relative to costs. Conversely, the deal benefited AstraZeneca, which needed revenue-generating drugs with remaining patent life. At the time of publication, the future disposition of BMS's diabetes portfolio after transition remained unclear.

## 2. HISTORY
BMS's 2013 exit from diabetes proved to be a strategically sound decision that reflected broader pharmaceutical industry dynamics. The diabetes market had become increasingly competitive with numerous generic options, particularly for older drugs like metformin and sulfonylureas, placing significant pricing pressure on branded medications.

Following the divestiture, BMS intensified its focus on oncology and immunology, achieving notable success. The company's immunotherapy drug Opdivo (nivolumab) received FDA approval in 2014 for melanoma and subsequently for multiple other cancer types, becoming a multi-billion dollar blockbuster. Other oncology drugs like Sprycel (dasatinib) and Yervoy (ipilimumab) also generated substantial revenue. BMS later acquired Celgene in 2019 for $74 billion, further strengthening its oncology and immunology portfolio.

AstraZeneca integrated the diabetes assets and continued development, though the diabetes market remained challenging. The company faced pricing pressures from payers and competition from newer drug classes like SGLT2 inhibitors and GLP-1 receptor agonists from competitors like Novo Nordisk and Eli Lilly.

Diabetes drug development has continued but with shifting focus toward cardiovascular risk reduction and weight management rather than purely glucose control, evidenced by the success of drugs like Ozempic and Jardiance that offer benefits beyond glycemic control.

## 3. PREDICTIONS
The original article contained limited explicit predictions beyond contextual analysis, but several implicit expectations can be evaluated:

• **BMS's oncology focus would yield better returns**: ✓ **Accurate**. BMS's oncology portfolio, particularly Opdivo and other immunotherapy drugs, generated substantially higher revenues and profit margins than diabetes drugs would have, validating the strategic shift.

• **Diabetes business was slow-moving with limited returns**: ✓ **Accurate**. The diabetes market evolved into a highly competitive, price-sensitive segment with numerous generic alternatives and payer pressures, confirming BMS's assessment of limited profitability potential.

• **AstraZeneca benefited from acquiring revenue-generating drugs**: ✓ **Partially accurate**. While AZ obtained immediate revenue streams, the diabetes portfolio faced ongoing pricing pressures and competition, limiting long-term growth potential compared to other therapeutic areas.

• **Market dynamics favored specialization over broad portfolios**: ✓ **Accurate**. The pharmaceutical industry continued shifting toward specialized, high-value therapeutic areas where companies could achieve dominant positions, rather than maintaining presence across all disease areas.

## 4. INTEREST
**Rating: 6**

This article captured a significant strategic realignment in the pharmaceutical industry, illustrating how large companies balance portfolio optimization against market dynamics. The move presaged broader industry trends toward specialization in high-value therapeutic areas, making it a notable case study in pharmaceutical strategy despite addressing a relatively routine business transaction.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20131219-bristol-myers-squibb-exits-diabetes.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_